Add Row
Add Element
cropper
update
National Cannabis Newswire
update
Add Element
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
March 10.2026
2 Minutes Read

Patient Protect Launches to Empower UK Medical Cannabis Patients Facing Discrimination

Protesters holding signs, advocating for change, cloudy day.

Empowering Medical Cannabis Patients in the UK

The recent launch of Patient Protect is a promising development for medical cannabis patients facing discrimination in the UK. This initiative, spearheaded by patient advocate Alex Fraser and cannabis lawyer Robert Jappie, seeks to provide vital support by filling in the gaps left by government services. With systematic discrimination still prevalent, Patient Protect aims to offer guidance, advocacy, and a collaborative legal approach for patients dealing with various issues, including policing, employment, housing, and driving.

Building a Community of Support and Evidence

Patient Protect operates as a subscription service for medical cannabis clinics, ensuring access is scalable for both larger and smaller entities. Until March 31, clinics can subscribe to the service; thereafter, it will remain free for patients to report incidents. This long-awaited initiative is pivotal in creating a national evidence base that highlights the extent of discrimination in the UK medical cannabis space, as current reports indicate many patients still endure significant stigma and misunderstanding from authorities.

A Call for Systemic Change and Education

Fraser emphasizes the need for a trusted platform where patients can report their experiences. By collating these reports, Patient Protect can not only empower individuals but also advocate for systemic reform. The recent guidance issued by the National Police Chiefs’ Council, although not a comprehensive solution, marks the beginning of an educational effort necessary for improving outcomes for patients within law enforcement and beyond.

Addressing the Bigger Picture: Legal Access for All Patients

The UK medical cannabis scene still faces significant challenges, particularly regarding legal access for patients. According to a recent campaign led by the Medical Cannabis Clinicians Society, 1.8 million patients currently rely on the illicit market due to restrictions on GP prescribing. The demand for changes in policy allowing general practitioners to prescribe medical cannabis could drastically alter the landscape for patients, as highlighted by supporters of the Protect Our Patients campaign.

Conclusion: A Collective Effort for Change

As Patient Protect steps into this crucial role, it invites executive cannabis professionals to reflect on how they can contribute to this movement toward better support and understanding of medical cannabis patients. By working collaboratively and advocating for changes that prioritize patient needs, the community can support the positive momentum now gathering in the UK.

To stay informed about ongoing changes and how you can help advocate for patient rights, consider following Patient Protect and related initiatives advocating for systemic reform and better access within the medical cannabis domain.

Brands

0 Views

0 Comments

Write A Comment

*
*
Related Posts All Posts

Empowering Workers: Unions and Medical Cannabis Patients Unite

Update Why Unions Are Key for Medical Cannabis PatientsAs more workers turn to medical cannabis as a legitimate treatment for a variety of health issues, understanding their rights and protections in the workplace is paramount. Unions play a vital role in advocating for these rights, yet their knowledge about medical cannabis varies widely. This gap leads to confusion and risks for many patients who face disciplinary action for lawful medical treatments.The Urgency of Educating UnionsIn most employment sectors, outdated drug policies fail to account for the legal status of medical cannabis, pushing patients into precarious situations. Rupa Shah of Releaf emphasizes that the communication between medical cannabis clinics and unions is crucial in enhancing the understanding of these issues. "Educating unions is just as important as educating employers and healthcare professionals," she notes. With awareness, unions can better support their members through disciplinary actions linked to medical cannabis prescriptions.Common Challenges Medical Cannabis Patients FacePatients often report feeling criminalized for adhering to a doctor's treatment plan. They may encounter punitive measures from employers after a positive drug test, which can happen despite holding a valid and legal prescription. The emotional toll this takes can be profound, leading to feelings of isolation and fear of workplace stigma. For those turning to unions for support, the level of assistance they receive can vary dramatically based on the union’s knowledge and approach to cannabis issues.Real-Life Impacts on PatientsConsider the case of a fast-food worker who was suspended after revealing her medical cannabis prescription. Despite her intention to communicate transparently, the lack of informed support from her union and employer escalated the problem. Such instances are not isolated; they highlight a broader issue where employees fear retribution for seeking treatment. Many patients express that having unions that are well-informed about medical cannabis would empower them to speak up without the fear of consequences.Strategies for Improvement: Unions, Clinics, and PatientsThe intersection of medical cannabis advocacy and workers' rights forms a crucial narrative in today’s labor discussions. Medical cannabis clinics can actively engage with unions by providing resources, training, and support for union representatives. This proactive approach can facilitate a more informed dialogue and more robust support systems for workers who depend on medical cannabis.Creating a Safer Workplace for Medical Cannabis UsersBoth clinics and unions must work together to establish clear policies that protect patients who utilize medical cannabis for managing their health. By fostering a culture of understanding and acceptance, it’s possible to create a safer, more supportive work environment for everyone. Such reforms can ultimately reduce stigma and help workers feel secure in their medical choices.Conclusion: Taking Action Toward ChangeThe conversation surrounding medical cannabis in the workplace is just beginning. As patients continue to advocate for their rights and unions enhance their knowledge, we can expect meaningful changes in workplace policies. Encouraging professional links between medical cannabis clinics and unions will be a major step, paving the way for an inclusive environment for all employees.

The Business of Cannabis Awards 2026: Celebrate Innovation and Leadership

Update Celebrating Cannabis Excellence: The 2026 Business of Cannabis AwardsThe Business of Cannabis Awards are back, lighting up London for their third iteration, scheduled for May 26, 2026. The annual event has quickly become the highlight of the European cannabis calendar, providing a platform to honor those who have made significant contributions to the industry since its inception in 2024. With 200 senior professionals attending last year, the event promises to be a gateway for networking and recognition, showcasing excellence, innovation, and leadership.Nominations Open: Every Voice MattersNominations for this year’s awards are officially open, and entry is entirely free of charge. This initiative emphasizes inclusivity, allowing businesses and individuals of all sizes and resources to seek recognition. As the cannabis industry evolves, it’s essential for all voices to be heard, and this opportunity paves the way for grassroots contributions to be acknowledged alongside established giants.New Award Categories Reflecting Industry GrowthThe 2026 awards will introduce three new categories: the Hannah Deacon Award, which pays tribute to a champion for patient rights; Consumer Technology Provider of the Year; and AgriTech Provider of the Year. These additions signal not only the maturity of the sector but also the expanding landscape that encompasses everything from consumer experiences to agricultural advancements. These new categories bring the total awards up to ten, a testament to the growing diversity and scope of the European cannabis industry.VIP Experience: Where Exclusivity Meets OpportunityFor the first time, the Business of Cannabis Awards will be part of Cannabis Europa’s newly curated VIP Experience. Geared towards senior executives, investors, and policymakers, this exclusive forum aims to provide a space for meaningful interactions and focused discussions on pivotal industry trends. Limited in size, the VIP Experience emphasizes quality connections, allowing attendees access to special briefings and roundtable discussions that elevate the overall event experience.A Broader Impact: Recognizing Excellence Across Two GroupsAs the business of cannabis flourishes in Europe, the awards recognize both organizational excellence and individual contributions. The group categories highlight achievements such as Cannabis Clinic of the Year, Cannabis Team of the Year, and Business Leader of the Year. Meanwhile, individual accolades like Industry Rising Star Award and International Journalist of the Year spotlight those making notable impacts in their respective areas of expertise.Join In: Be Part of the ConversationAs the cannabis sector continues to mature, the importance of recognizing collaborative efforts and groundbreaking advancements cannot be understated. The Business of Cannabis Awards not only showcase excellence but also serve as a catalyst for industry dialogue and innovation. Senior executives, investors, and cannabis enthusiasts alike are encouraged to participate in this celebration of growth. Tap into the evolving narrative of European cannabis by nominating and attending this momentous event!

How Ananda Pharma's NHS-Backed CBD Trial Could Revolutionize Endometriosis Treatment

Update A Breakthrough in Endometriosis Treatment Ananda Pharma has recently made significant strides in the ongoing battle against endometriosis, a condition that affects approximately 10% of women worldwide. The company has received official approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to commence dosing in its pivotal ENDOCAN Phase 2 clinical trial. This trial, which will utilize Ananda's proprietary MRX1 CBD oral solution, seeks to assess its efficacy in alleviating endometriosis-associated pain. What's Unique About the ENDOCAN Trial? Led by renowned experts from the University of Edinburgh, this double-blind, placebo-controlled trial not only employs rigorous scientific methodology but also aims to address a significant gap in existing studies, which have often relied on observational models. This trial's strict eligibility criteria ensure that the participants have a clinically confirmed diagnosis of endometriosis, setting a standard for safety and efficacy from the outset. A Historical Perspective on CBD and Endometriosis Historically, research into the use of cannabinoids for treating endometriosis has been limited. However, recent publications have begun to shed light on the potential benefits of CBD in managing this complex condition. A peer-reviewed article published by Dr. Lucy Whitaker and her team emphasizes CBD's analgesic, anti-inflammatory, and neuroprotective effects, reinforcing the scientific community's growing interest. The Road to Regulatory Approval Melissa Sturgess, CEO of Ananda Pharma, highlights that this trial is different from others currently being conducted. "This study could lead to a product that is fully approved for prescription on the NHS," she stated. This represents a hopeful turning point for women suffering from endometriosis, who have often found limited relief through conventional treatments. Implications Beyond Endometriosis The design of the ENDOCAN trial includes potential implications beyond just pain relief for endometriosis. The high doses of MRX1, reaching milestones not typical in over-the-counter CBD products, could pave the way for a broader understanding of CBD's potential applications. This trial's safety data may contribute to future discussions on CBD regulations, potentially allowing higher dosages and more extensive therapeutic uses. The Community Impact This research not only highlights Ananda's commitment to advancing cannabinoid-based therapies but also fosters community engagement in health initiatives. As the trial unfolds, sharing experiences and outcomes could galvanize local and national support for increased funding and research into cannabis-based treatments. By prioritizing transparency and patient involvement, Ananda aims to create a supportive environment for women navigating the challenges of endometriosis. Future Prospects in Cannabis Research The ENDOCAN trial represents an essential leap toward understanding the therapeutic role of CBD in painful conditions, reflecting a shift in medical paradigms regarding cannabis. As Ananda continues to push forward with this research, it stands poised to lead a transformation in how chronic pain conditions are managed. With the final outcomes expected in the near future, the medical community and patients alike are waiting with anticipation.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*